The French-U.S. company Novadiscovery has hailed a “watershed moment for clinical trial design” as its trial simulation tool successfully predicted the outcome of a phase 3 oncology trial run by AstraZeneca.
New guidelines have been issued by the FDA called Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials. Curavit was ahead of the game with its plans, find out how.
Kicking off a series of DIA Global interviews in Boston, OSP had the pleasure of speaking to Cal Collins, co-founder and CEO of OpenClinica - a company that wants to empower data managers, clinical researchers, and study participants.
The US Food and Drug Administration will soon require researchers and companies seeking approval for late-stage clinical trials to submit a diversity plan for trial participants. Scott Gray, CEO of Clincierge, discusses how trial sponsors and CROs can...
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
Social, cultural, and financial barriers pose a challenge in enrollment for oncology clinical trials, but USC investigator believes mitigating barriers to diversify research may provide comprehensive data.
Smaller company’s last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from the need to scale infrastructure, says Tufts director.
It is critical to understand the patient and site perspective to “maximize opportunities and minimize challenges” associated with the use of mobile technology in clinical trials, says CTTI executive director.
A year after implementing its policy on the publication of clinical data, reports on 50 medicines have been published and more than 80,000 documents downloaded – outcomes achieved through industry collaboration, says EMA.